By WSJ Staff
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Consumers will now be able to access NovoCare Pharmacy through Him & Hers' platform as well as clinical support, nutrition guidance and a membership, the companies said in a statement Tuesday.
"We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future," said Andrew Dudum, chief executive and founder of Hims & Hers.
"Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk's innovative medications with Hims & Hers ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affordably," said Dave Moore, executive vice president of U.S. operations and global business development and president of Novo Nordisk.
(END) Dow Jones Newswires
April 29, 2025 07:31 ET (11:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.